All In Biotech

Drug Trial Radar · NCT07820813

bNAbs and Anti-PD-1 in HIV

Inducing Durable Immunological Control of HIV-1 Through Administration of Long-acting Broadly Neutralizing Antibodies and Low-dose Anti-PD-1 - a Randomized, Double-blinded, Placebocontrolled Trial (the IDUNN Trial)

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Oct 7, 2026

Primary completion

Sep 15, 2029

Study completion Sep 15, 2030

Sponsor

Lead sponsor
Ole Schmeltz SøgaardAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Aalborg University Hospital; Gødstrup Hospital; Odense University Hospital; Hvidovre University Hospital; Copenhagen University Hospital, Rigshospitalet; Oslo University Hospital; Karolinska University Hospital; Landspitali University Hospital
First posted
Sep 15, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Antiretroviral therapy (ART) has significantly extended the life expectancy of people living with HIV-1 (PLWH), but it does not cure the infection. Broadly neutralizing antibodies (bNAbs), such as 3BNC117 and 10-1074, not only neutralize circulating virus but also engage the immune system to enhance HIV-1-specific CD8+ T cell responses and stimulate autologous neutralizing antibody production. In some individuals who discontinue ART, bNAb treatment resulted in long-term post-treatment control. However, a major obstacle to immunotherapeutic strategies in PLWH is the immune dysfunction that persists despite long-term suppressive ART. One contributing factor is the immune checkpoint receptor programmed death-1 (PD-1), which is expressed on T cells and suppresses their function when engaged by its ligands. Blocking PD-1 with monoclonal antibodies (mAbs) can reverse T cell exhaustion, a strategy that has resulted in extraordinary increases in survival and cure in cancer treatment and in ex vivo and animal studies of HIV. These findings support the rationale for incorporating PD-1 inhibition in HIV cure strategies. Low-dose nivolumab, an anti-PD-1 mAb, has been shown to be safe in clinical trials. The hypothesis is that combining a single low-dose of nivolumab with long-acting bNAbs (3BNC117-LS and 10-1074-LS) during an analytical treatment interruption (ATI) will reduce T cell exhaustion and boost HIV-1-specific immune responses, as a novel strategy to induce sustained virological control without ART even after the bNAbs have been cleared from the body.

Conditions

  • HIV-1

Interventions

  • 3BNC117-LSDrug

    bNAb; 30 mg/kg

  • 10-1074-LSDrug

    bNAb; 10 mg/kg

  • NivolumabDrug

    Anti-PD-1a; low dose 1.0 mg/kg

  • PlaceboOther

    Saline

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time from the day of stopping ART to the day of meeting criteria for loss of immunological control of HIV-1 (defined below)Time frame: 60 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Aarhus University Hospital

    Aarhus, Denmark · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.